Compositions and methods for treating neonatal biliary atresia

Abstract

Disclosed are methods and compositions for treatment of a subject having a biliary disorder. The methods include administering a therapeutically effective amount of a serine protease inhibitor to a subject in need thereof. The biliary disorder include biliary atresia, a biliopathy, Primary Biliary Cirrhosis (PBC), Primary Sclerosing Cholangitis (PSC), and combinations thereof. In certain aspects, the serine protease inhibitor may be a protease inhibitor rC1 Inhibitor.

Description

CROSS-REFERENCE TO RELATED APPLICATIONS[0001]This application claims priority to and benefit of International Application No. PCT / US2016 / 033858, entitled “Compositions and Methods for Treating Neonatal Biliary Atresia,” filed May 24, 2016, which claims the benefit of and priority to U.S. Provisional Patent Application Ser. No. 62 / 170,261, filed Jun. 3, 2015, the contents of which are incorporated by reference in their entirety for all purposes.BACKGROUND[0002]Biliary Atresia (BA) is a pediatric liver disease restricted to newborn infants with no known medical treatment. BA is a rare neonatal disease manifesting only in the first few weeks of life characterized by ascending obstruction of the biliary tree resulting in severe cholestasis and rapidly progressing biliary cirrhosis. The common histopathological picture is one of inflammatory damage to the intra- and extrahepatic bile ducts with sclerosis and narrowing or obliteration of the biliary tree. BA is a rapidly progressing oblit...

AI Technical Summary

Benefits of technology

The patent is about methods and compositions for treating biliary disorders in humans. The methods involve giving a therapeutic amount of a serine protease inhibitor to patients in need. Biliary disorders that can be treated include biliary atresia, biliopathy, PBC, PSC, and combinations thereof. The serine protease inhibitor may be a specific inhibitor called rC1 Inhibitor.

Problems solved by technology

Children who develop BA are born jaundice-free; however, within the first weeks of life, the extrahepatic biliary tree develops inflammation leading to duct obstruction and loss of bile flow.

Untreated, this condition leads to cirrhosis and death within the first years of life.

The incidence of B.A is approximately 1:10-15,000 of live births and is classified as a rare disease by NORD (National Organization of Rare Disorders) end NODK, Children who develop BA are born jaundice-free; however, within the first weeks of life, the extrahepatic biliary tree develops inflammation leading to duct obstruction and loss of bile flow.

The baby suffers from acholic (chalk-colored) stools, yellowing of skin, enlarged liver and spleen, ascites develops with rapidly progressing liver injury and cirrhosis, and the baby suffers from loss of weight, becomes irritable and has worsening jaundice.

Infants with BA are severely ill and may face developmental challenges even after liver transplantation.

Because of the severe clinical manifestations and limited therapeutic options, most infants progress to end-stage liver cirrhosis, portal hypertension and liver failure eventually needing liver transplantation.

While the postsurgical medical management combines nutrition, antibiotics, choleretics, and possibly anti-inflammatory medications, the impact of these practices on the clinical outcome is unclear, and there are no medical therapies available to prevent ongoing liver injury following a Kasai procedure.

Further, infants having a “failed Kasai” will require a liver transplant in infancy to survive, and infants diagnosed too late have too much liver damage to benefit from Kasai and will require early transplant.

Post-operative complications are also significant in that some patients, even after successful bile drainage, can still experience cholangitis and succumb to infection.

This is further compounded by a complete lack of medical interventions.

However, the role of corticosteroids in improving bile flow is controversial.

Indeed, several clinical trials including the most recent and extensive trial of corticosteroid therapy in the US following Kasai (ChiLDREN; START trial: NCT00294684) showed that steroids alone do not prevent the need for liver transplantation.